⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9112837 | 0.71 | — | — | |
| SCHEMBL29085808 | 0.69 | — | — | |
| SCHEMBL1098470 | 0.67 | — | — | |
| SCHEMBL1868283 | 0.67 | — | — | |
| SCHEMBL5357128 | 0.67 | — | — | |
| SCHEMBL1052073 | 0.67 | — | — | |
| SCHEMBL1318768 | 0.67 | — | — | |
| SCHEMBL17174420 | 0.67 | — | — | |
| SCHEMBL1099053 | 0.67 | — | — | |
| SCHEMBL1052070 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 460 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111718332-B | 2-substituted pyrazol amino-4-substituted amino-5-pyrimidine formamide compound, composition and application thereof | 北京赛特明强医药科技有限公司 | 2021-08-17 | — | — | CN | claimed |
| CN-111718332-A | 2-substituted pyrazol amino-4-substituted amino-5-pyrimidine formamide compound, composition and application thereof | 北京赛特明强医药科技有限公司 | 2020-09-29 | — | — | CN | claimed |
| US-10201525-B2 | Tetrazole-substituted arylamides as PX2 and PX2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2019-02-12 | — | — | US | claimed |
| EP-2976339-B1 | GEMINALLY SUBSTITUTED CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-06-27 | — | — | EP | claimed |
| US-9957264-B2 | Geminally substituted cyanoethylpyrazolo pyridones as Janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-05-01 | — | — | US | claimed |
| EP-2976338-B1 | N-(2-CYANO HETEROCYCLYL)PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-01-03 | — | — | EP | claimed |
| CN-105189498-B | Geminally substituted cyanoethylpyrazolopyridinones as JANUS kinase inhibitors | 默沙东公司 | 2017-06-27 | — | — | CN | claimed |
| US-20170143672-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES AS PX2 AND PX2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2017-05-25 | — | — | US | claimed |
| US-9593128-B2 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | HOFFMANN-LA ROCHE INC. (US) | 2017-03-14 | — | — | US | claimed |
| US-20160272632-A1 | GEMINALLY SUBSTITUTED CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-09-22 | — | — | US | claimed |
| JP-2007506716-A | — | — | 2007-03-22 | — | — | JP | claimed |
| EP-1756088-A1 | QUINAZOLINE DERIVATIVES AS ERBB RECEPTOR TYROSINE KINASES | AstraZeneca AB (SE) | 2007-02-28 | — | — | EP | claimed |
| US-20070043010-A1 | Quinazoline derivatives | ASTRAZENECA UK LIMITED (GB) | 2007-02-22 | — | — | US | claimed |
| EP-1670786-A1 | QUINAZOLINE DERIVATIVES | Astrazeneca AB (SE) | 2006-06-21 | — | — | EP | claimed |
| WO-2005118572-A1 | QUINAZOLINE DERIVATIVES AS ERBB RECEPTOR TYROSINE KINASES | ASTRAZENECA AB (SE) | 2005-12-15 | — | — | WO | claimed |
| US-6960609-B2 | 1-diphenylmethyl-pyrazole derivatives as opioid receptor ligands | PFIZER, INC. (US) | 2005-11-01 | — | — | US | claimed |
| WO-2005030757-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-04-07 | — | — | WO | claimed |
| US-20030069241-A1 | 1-Diphenylmethyl-pyrazole derivatives as opioid receptor ligands | PFIZER INC. | 2003-04-10 | — | — | US | claimed |
| EP-1279666-A1 | 1-diphenylmethyl-pyrazole derivatives as opioid receptor ligands | Pfizer Products Inc. (US) | 2003-01-29 | — | — | EP | claimed |
| WO-1992022545-A1 | NEW COUMARIN DERIVATIVES | FIDIA S.P.A. (IT) | 1992-12-23 | — | — | WO | claimed |